Overview

Citalopram Titration in Early Non-responder Patients With Major Depressive Disorders

Status:
Completed
Trial end date:
2018-12-08
Target enrollment:
Participant gender:
Summary
Major depressive disorder is a common mental disorder and the leading cause of disability worldwide. According to the Canadian Network for Mood and Anxiety Treatment, early improvement following an antidepressant treatment is correlated with response and remission. Escalation of an antidepressant dose after 2 weeks, as opposed to 4 to 8 weeks, is proposed to favor early improvement. However, this has never been tested systematically in a controlled study involving major depressive disorder patients that are non-responders to their antidepressant treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Ciusss de L'Est de l'Île de Montréal
Treatments:
Citalopram
Dexetimide